Interactions between e-mycin(erythromycin) and Conivaptan (conivaptan)
erythromycin and conivaptan (Major Drug-Drug)
CONTRAINDICATED: Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of conivaptan, which is primarily metabolized by the isoenzyme. The interaction has been studied with orally administered conivaptan and ketoconazole, a potent CYP450 3A4 inhibitor. According to the product labeling, coadministration of oral conivaptan 10 mg with ketoconazole 200 mg resulted in a 4-fold increase in the peak plasma concentration (Cmax) and an 11-fold increase in the area under the plasma concentration-time curve (AUC) of conivaptan. The consequences of increased conivaptan concentrations are unknown.
MANAGEMENT: The use of conivaptan with potent CYP450 3A4 inhibitors such as itraconazole, ketoconazole, voriconazole, nefazodone, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics is considered contraindicated.
